Retinal thickness changes following photodynamic therapy in chronic central serous chorioretinopathy.
OBJECTIVE
To evaluate changes in neural retina (NR) thickness and best-corrected visual acuity (BCVA) induced by treatment of chronic central serous chorioretinopathy (CSC) by photodynamic therapy (PDT).


METHODS
Retrospective study of 25 eyes of 25 patients with chronic CSC treated by "full-fluence" PDT. LogMAR BCVA and Stratus optical coherence tomography (OCT) were evaluated before treatment and 1 year after PDT. Twenty-four eyes from 24 patients with non-chronic, non-PDT-treated forms of CSC were evaluated as a control group.


RESULTS
NR foveal thickness before PDT was 182 ± 43.4 μm (range, 92-246) vs 148.1 ± 30.9 μm (range, 101-220) 1 year after treatment (p = 0.004; Student's t-test paired data). NR foveal thickness in the untreated eyes was 204.6 ± 30.7 μ (range, 132-249) vs 192.5 ± 26.4 μ (range, 123-235) after self-resolution (p = 0.03; Student's t-test paired data). Basal NR thickness was statistically significant different between both groups (p = 0.04; Student's t-test); this difference continued to be significant at the end of the follow-up (p < 0.01; Student's t-test). All the patients with chronic CSC treated by PDT showed anatomic resolution, and BCVA improved from 0.38 ± 0.35 to 0.23 ± 0.29 (p = 0.007; Student's t-test paired data). Final BCVA and basal and final NR thickness showed poor correlation (Pearson = 0.2 and 0.1 respectively).


CONCLUSIONS
The use of PDT in chronic CSC induces NR thickness thinning. This change is not correlated with a decrease in BCVA. Spontaneous resolution of classic CCS also showed significant NR thinning.
Castilla La Mancha University, Albacete, Spain. sergiocp.ab@gmail.com
Sergio
S
Copete
Jose M
JM
Ruiz-Moreno
Carlos
C
Cava
Javier A
JA
Montero
D000328:Adult; D000368:Aged; D016022:Case-Control Studies; D056833:Central Serous Chorioretinopathy / Q000503:physiopathology / Q000601:surgery*; D002908:Chronic Disease; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010778:Photochemotherapy; D017319:Photosensitizing Agents / Q000627:therapeutic use; D011166:Porphyrins / Q000627:therapeutic use; D012160:Retina / Q000473:pathology*; D012164:Retinal Diseases / Q000175:diagnosis*; D012189:Retrospective Studies; D041623:Tomography, Optical Coherence; D000077362:Verteporfin; D014792:Visual Acuity / Q000502:physiology
D017319:Photosensitizing Agents; D011166:Porphyrins; D000077362:Verteporfin